A. V. Kamynina

Acetylcholine and antibodies against the acetylcholine receptor protect neurons and astrocytes against beta-amyloid toxicity

Aggregated amyloid-β causes pathological changes in mixed cultures of neurons and astrocytes such as sporadic cytoplasmic intracellular Ca(2+)-signalling, increase in reactive oxygen species production and cell death. Some of the toxic effects of amyloid-β are mediated through the interaction of the peptide with α7-type nicotinic acetylcholine receptors at the cell surface. Here we demonstrated that affinity purified antibodies to synthetic fragment 173-193 of the α7-subunit of the nAChR are able to protect cells from amyloid-β induced cell death. The antibodies had no effect on the amyloid-β induced calcium signal in astrocytes. However, they significantly reduced amyloid-β induced and NADPH oxidase mediated ROS production. Modulation of the NADPH oxidase activity by either the antibodies, the receptor agonist acetylcholine or the antagonist of the α7-type nicotinic acetylcholine receptors α-bungarotoxin was vital in inhibiting both amyloid-β induced ROS production, caspase 3 cleavage as well as cell death. The uncovered details of the mechanism underlying the action of antibodies to α7-type nicotinic acetylcholine receptors gives additional insight into the involvement of this receptor in Alzheimers disease pathology and provides a new approach to anti-Alzheimers disease vaccine design.

Immunization with either prion protein fragment 95-123 or the fragment-specific antibodies rescue memory loss and neurodegenerative phenotype of neurons in olfactory bulbectomized mice

Epidemiological studies demonstrated association between head injury (HI) and the subsequent development of Alzheimers disease (AD). Certain hallmarks of AD, e.g. amyloid-β (Aβ) containing deposits, may be found in patients following traumatic BI (TBI). Recent studies uncover the cellular prion protein, PrP(C), as a receptor for soluble polymeric forms of Aβ (sAβ) which are an intermediate of such deposits. We aimed to test the hypothesis that targeting of PrP(C) can prevent Aβ related spatial memory deficits in olfactory bulbectomized (OBX) mice utilized here to resemble some clinical features of AD, such as increased level of Aβ, memory loss and deficit of the CNS cholin- and serotonin-ergic systems. We demonstrated that immunization with the a.a. 95-123 fragment of cellular prion (PrP-I) recovered cortical and hippocampus neurons from OBX induced degeneration, rescued spatial memory loss in Morris water maze test and significantly decrease the Aβ level in brain tissue of these animals. Affinity purified anti-PrP-I antibodies rescued pre-synaptic biomarker synaptophysin eliciting similar effect on memory of OBX mice, and protected hippocampal neurones from Aβ25-35-induced toxicity in vitro. Immunization OBX mice with a.a. 200-213 fragment of cellular prion (PrP-II) did not reach a significance in memory protection albeit having similar to PrP-I immunization impact on Aβ level in brain tissue. The observed positive effect of targeting the PrP-I by either active or passive immunization on memory of OBX mice revealed the involvement of the PrP(C) in AD-like pathology induced by olfactory bulbectomy. This OBX model may be a useful tool for mechanistic and preclinical therapeutic investigations into the association between PrP(C) and AD.

Vaccination with Peptide 173-193 of Acetylcholine Receptor α7-Subunit Prevents Memory Loss in Olfactory Bulbectomized Mice

We studied the ability of four non-conjugated alpha7-subunit fragments of the nicotinic acetylcholine receptor to induce an immune response and to protect memory in olfactory bulbectomized mice which demonstrate abnormalities similar to Alzheimers disease (AD). Vaccination only with the alpha7-subunit fragment 173-193 was shown to rescue spatial memory, to restore the level of alpha7 acetylcholine receptors in the cortex, and to prevent an increase in the amyloid-beta (Abeta) level in brain tissue in these animals. Antibodies against the peptide 173-193 were revealed in blood serum and cerebrospinal liquid in the bulbectomized mice. Passive immunization with mouse blood sera containing antibodies to the peptide 173-193 also restored memory in bulbectomized animals. The observed positive effect of both active and passive immunization with the fragment of alpha7-subunit on memory of bulbectomized mice provides a new insight into an anti-AD drug design.

Immunization with a synthetic fragment 155–164 of neurotrophin receptor p75 prevents memory loss and decreases beta-amyloid level in mice with experimentally induced Alzheimer’s disease

Neurotoxic beta-amyloid peptide plays an important role in the pathology of Alzheimer’s disease. In aggregated form it binds to several proteins on the surface of the brain cells leading to their death. p75 receptor involved in supporting of cell balance is one of the targets for toxic beta-amyloid. We proposed that induction of antibodies against potential binding sites of p75 with beta-amyloid can be a promising approach towards development of new anti-Alzheimer’s disease treatment. Four potentially immunoactive fragments of p75 were chosen and chemically synthesized. Investigation of immunoprotective effect of the peptide fragments carried out in mice with experimentally induced form of Alzheimer’s disease helped to reveal two fragments effectively preserving murine memory from impairment. Results obtained by ELISA biochemical analysis showed that only immunization with fragment p75 155–164 led to significant decrease in beta-amyloid level in the brain of the experimental mice. Thus, immunization with both fragments of p75 receptor pro-vides a new insight into anti-Alzheimer’s disease drug design.

New approaches to the immunotherapy of Alzheimer’s disease with the synthetic fragments of α7 subunit of the acetylcholine receptor

The effect of immunization with the synthetic fragments of the α7 subunit of the acetylcholine nicotine receptor on the spatial memory of mice subjected to olfactory bulbectomy, which causes the development of the neurodegenerative disease of Alzheimer’s type, was studied. NMRI mice were immunized with the KLH conjugates of two peptide fragments of the N-terminal fragment of the α7 subunit extracellular fragment, subjected to olfactory bulbectomy to cause the development of the neurodegenerative disease of Alzheimer’s type, and then the state of the spatial memory was evaluated. It was shown that 20% of bulbectomized mice immunized with N-terminal 1–23 fragment exhibited good spatial memory after training. Immunization with the peptide construct (159–167)-(179–188) consisting of two hydrophilic exposed regions of α7-subunit induced good spatial memory in 50% of bulbectomized mice, while in the control group, which received only KLH, none of animals were learned. Thus, the development of immunotherapy with peptide (159–167)-(179–188) seems to be a promising approach to prophylaxis and treatment of Alzheimer’s disease.

A fragment of the receptor for advanced glycation end products restores the spatial memory of animals in a model of Alzheimer’s disease

The ability of some synthetic peptides modeling the potentially important regions of four membrane proteins, known as cell targets for beta-amyloid, to restore the spatial memory of animals in an experimental model of Alzheimer’s disease has been studied. Nine fragments of the protein receptor for advanced glycation end products (RAGE), which, according to X-ray structure analysis data, repeat all its exposed nonstructural regions, have been synthesized. The effect of these peptides and of earlier synthesized immunoprotective fragments of three other proteins (alpha7-type acethylcholine receptor, the prion protein, and the neurotrophin receptor p75) has been studied on intranasal administration, which excludes the development of the immune response to the peptide. It has been shown that only one fragment, RAGE (60–76), exhibits a therapeutic activity, by restoring the spatial memory of bulbectomized mice and decreasing the level of the brain beta-amyloid.

Protective activity of fragments of the prion protein after immunization of animals with experimentally induced Alzheimer’s disease

The prion protein is considered as one of the membrane targets of the neurotoxic beta-amyloid during development of Alzheimer’s disease. We chose and synthesized peptide fragments that corresponded to the 17–33, 23–33, 95–110, and 101–115 sequences of the prion protein and are responsible for the betaamyloid binding. The effect of immunization with the peptides on the development of symptoms of Alzheimer’s disease was investigated on animals with an experimentally induced form of the disease. Immunization with either free 17–33 peptide or with protein conjugates of the 23–33 and 101–115 peptides was shown to restore spatial memory of the animals. Immunization with the 17–33 peptide was also shown to decrease the level of brain beta-amyloid and to recover morphofunctional parameters of the brain.

Structure–Function mapping of the extracellular part of neurotrophin receptor P75

Receptor p75 is a classical membrane receptor, which consists of an extracellular region, a transmembrane region, and an intracellular C-terminus death domain. p75 is involved in the activation of neurotrophic factors and plays an essential role in the regulation of cell functions such as proliferation, differentiation, synaptogenesis, neuronal plasticity, and survival or apoptosis. It is supposed that p75 accelerates the positive effects of neurotrophins being a part of the complex with the Trk receptor; however, in the absence of Trk receptors, the interaction between p75 and neurotrophins leads to cell apoptosis. The interest in the p75 receptor has increased dramatically in the past few years, as it has been shown that p75 may play a crucial role in the genesis of neurodegenerative disorders, in particular, Alzheimer’s disease. The interaction between p75 and β-amyloid leads to neuronal death in the brain. Identification of the p75 regions involved in the development of pathology is of great importance for understanding the mechanisms of Alzheimer’s disease and for creating targeted therapeutic agents for this disorder. In the present work, immunological approaches have been used for structure-function mapping of the extracellular domain of the p75 receptor during the development of a neurodegenerative process in olfactory bulbectomized animals. The nine extracellular regions selected on the basis of X-ray structure analysis of p75 molecule hypothetically could include β-amyloid binding sites and participate in the progression of pathology. Peptides with the amino acid sequences analogous to the selected regions were synthesized. Immunization with such fragments conjugated with hemocyanin induced the formation of antipeptide antibodies in experimental animals. However, only immunization with fragment (167–176) prevented the memory loss and neuronal death in the cortex and hippocampus of bulbectomized mice. This fragment had no effect on sham-operated mice. The results indicate that fragment (167–176) of the p75 sequence deserves further research as a potential basis of the targeted immunotherapy of Alzheimer’s disease.

Antibodies to synthetic fragment 95–123 of the prion protein protect neurons and astrocytes from beta-amyloid toxicity

Molecular mechanisms of β-amyloid toxic effect on brain cells during Alzheimer’s disease is associated with oxidative stress, intracellular Ca2+ increase in neurons and astrocytes and activation of reactive oxygen species production. Prion protein is known to be involved in beta-amyloid toxicity. Here we investigated an effect of affinity purified antibodies to synthetic fragment 95–123 of the prion protein (PrP-(95–123)) on β-amyloid induced cell death, Ca2+-signal, reactive oxygen species production and caspase 3 activation. We have shown that antibodies to PrP-(95–123) are able to protect neurons and astrocytes from beta-amyloid induced cell death with no effect on the intracellular Ca2+ concentration altered by beta-amyloid treatment. However, the antibodies significantly reduced β-amyloid induced reactive oxygen species production in astrocytes and decreased caspase 3 activation in neurons and astrocytes. Thus, induction of antibodies to PrP-(95–123) of the prion protein provides a new approach to anti-Alzheimer’s disease vaccine design.

Antibodies to synthetic fragments of nucleophosmin for the specific detection of its monomeric and oligomeric forms

Immunoactive fragments corresponding to the N-terminal (19–36) and C-terminal (283–294) regions of the NPM1.1 isoform of nucleophosmin and their shortened fragments were chosen and synthesized. Rabbits were immunized with free full-size peptides and their protein conjugates. Antibodies produced against the 19–36 and 283–294 peptides were purified by affinity chromatography on cyan-bromide activated sepharose that was preliminary conjugated with the synthetic peptides. An analysis of immunoblots of lysates of the HeLa and Ramos cells demonstrated that the antibodies produced against the 19–36 peptide detected the monomeric form of nucleophosmin, whereas the antibodies against the 283–294 peptide predominantly revealed its oligomeric form. It was established by immunocytochemical analysis that the antibodies induced by the 19–36 peptide stained the nucleoplasm and perinuclear space of the cytoplasm of the HeLa and Ramos cells, but did not stain the nucleoli, while the antibodies against the 283–294 peptide stained only the nucleoli of the same cells. On the basis of these results, one could propose that the monomeric and oligomeric forms of nucleophosmin were located in the nucleoplasm and nucleoli of the examined cells, respectively. Thus, antibodies which can predominantly detect monomeric and oligomeric forms of nucleophosmin were produced for the first time. An analysis of the monomeric-oligomeric state and the localization of the nucleophosmin in tumor cells could be performed using these antibodies.